Deliver First-of-its-Kind Comprehensive Remote Pregnancy Care Solution

WASHINGTON (PRWEB) OCTOBER 12, 2021

Babyscripts, the leading virtual care platform for managing obstetrics, announced today that they are entering into a collaboration with Nuvo Group, a company commercializing INVU by Nuvo™, an FDA-cleared, prescription-initiated, remote pregnancy monitoring platform. This collaboration will offer non-stress tests by INVU, within Babyscripts’ commercial ecosystem, with the singular goal of advancing pregnancy care delivery for providers and their patients, particularly those at high risk for complications.

Babyscripts Virtual Maternity Care solution allows providers to deliver risk-specific care to pregnant mothers at any time, in any place. By integrating Nuvo’s INVU technology into Babyscripts Virtual Maternity Care platform, Babyscripts’ capabilities will extend to provide a more comprehensive remote pregnancy care platform that builds on Babyscripts existing solution for (i) patient education/engagement, (ii) remote monitoring tools, and (iii) improved care analytics to inform better outcomes. This collaboration is particularly focused on providing the highest standard of care for at-risk mothers, at a time when access to care has been compromised by the pandemic.

The collaboration between Babyscripts and Nuvo Group reflects the companies’ shared vision to embrace digital point-of-care solutions to provide better access to care for all health populations regardless of risk, race, or income; leveraging remote monitoring and management to improve care coordination and reduce clinical and social barriers to care. The collaboration responds to market demand for comprehensive remote solutions, which became acute during the pandemic and has continued to increase as patients expect to receive care outside of the clinic and care providers are looking for ways to extend services in the midst of resource limitations.

Nuvo’s INVU platform is a first-to-market product that democratizes access to medical grade care, enabling expectant moms to be more compliant with prescribed care,” said Debra Bass, U.S. President Nuvo Group. “Babyscripts provides the commercial infrastructure to expand access to INVU to a segment of pregnant women who are underserved in today’s brick and mortar care delivery system.”

Nuvo CEO, Kelly Londy, added, “Nuvo is excited to embark on this partnership that leverages the care ecosystem to deliver against the Nuvo mission to give every life a better beginning.”

Babyscripts Virtual Maternity Care solution includes a digital education layer with daily gestational-age and practice-specific, customizable content extending through one year postpartum, delivering content to the patient via a mobile app. Through connected or manual medical devices and risk assessments, Babyscripts also enables remote monitoring and management of pregnant patients dependent on mental health or blood pressure-related risk (including low-risk, chronic hypertension, gestational hypertension, and postpartum hypertension).

About Babyscripts

Babyscripts is delivering a new model for prenatal and postpartum care that is transforming the way expectant mothers use technology to work with their healthcare providers. We’ve spent the last seven years delivering the most-implemented mobile clinical solution for remote monitoring in pregnancy, with the mission to eliminate maternal mortality and improve access to care for all mothers. Babyscripts was named to the 2020 Digital Health 150, CB Insights’ annual ranking of the 150 most promising private digital health companies in the world. For more information on our virtual care solution and to request a demo, visit https://babyscripts.com/.

About Nuvo Group

Nuvo Group is committed to serving providers and expectant mothers by advancing pregnancy care with new technology, tools, and practices. The INVU platform combines proprietary hardware for data collection, innovative cloud-based software for computational power and AI tools to optimize the pregnancy care experience on a global scale. INVU received a 510(k) clearance from the U.S. FDA for maternal and fetal heart rate monitoring in 2020 and a supplemental clearance for remote monitoring of uterine activity in May of 2021. Company leadership is comprised of experienced business and medical professionals, dedicated data engineers, software designers and proud parents who embrace a collective mission to give every life a better beginning.

For more information and complete indications, contraindications, warnings and precautions along with instructions for use, visit: http://www.nuvocares.com.